MFN1 augmentation prevents retinal degeneration in a Charcot-Marie-Tooth type 2A mouse model

Area of Science:

• Neuroscience
• Genetics
• Ophthalmology

Background:

• Charcot-Marie-Tooth disease type 2A (CMT2A) is a common inherited peripheral neuropathy.
• Mutations in the Mitofusin2 (MFN2) gene, particularly R94Q, are linked to CMT2A.
• CMT2A presents with progressive motor/sensory loss and visual impairments.

Purpose of the Study:

• To investigate retinal functional and morphological changes in a CMT2A mouse model.
• To elucidate the role of mitochondrial dynamics in CMT2A-associated retinal degeneration.
• To explore therapeutic potential of MFN1 augmentation.

Main Methods:

• Utilized a transgenic mouse model (MFN2 R94Q mutation).
• Assessed retinal morphology and function, including photoreceptor and retinal ganglion cell integrity.
• Analyzed mitochondrial fusion/fission dynamics and mitophagy pathways (P62/LC3B, PINK1/Parkin).

Main Results:

• CMT2A mice exhibited significant vision loss, photoreceptor degeneration, and retinal ganglion cell loss.
• Mitochondrial MFN1/MFN2 imbalance and dysregulated fusion/fission were observed.
• MFN1 augmentation in MFN2 mutant mice rescued vision and retinal structure by restoring mitochondrial homeostasis and mitophagy.

Conclusions:

• MFN2 mutations cause retinal degeneration in CMT2A through disrupted mitochondrial dynamics and mitophagy.
• MFN1 augmentation represents a potential therapeutic strategy for vision loss in CMT2A.
• Restoring mitochondrial homeostasis is key to preventing neurodegeneration in CMT2A.